Ziv-aflibercept correlated with BCVA, CMT improvements

Visual acuity improved beyond that expected in relation to reduction in central macular thickness when a 2.5 mg dose of intravitreal ziv-aflibercept was used in patients with diabetic macular edema, according to a study.
CMT and BCVA were evaluated over the course of 1 year of treatment with 2.5 mg or 1.25 mg of intravitreal ziv-aflibercept (IVZ; Zaltrap, Regeneron) compared with 1.25 mg bevacizumab (IVB; Avastin, Genentech) in eyes with DME.
The study included 42 eyes in the 2.5 mg IVZ cohort, 42 eyes in the 1.25 mg IVZ cohort (Read more...)

Full Story →